Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)



Status:Completed
Conditions:High Cholesterol
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:8/3/2018
Start Date:February 4, 2015
End Date:July 23, 2018

Use our guide to learn which trials are right for you!

An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia

This is an open-label, single-arm study to assess the reduction of low-density lipoprotein
cholesterol (LDL-C) by REGN1500 in patients with homozygous familial hypercholesterolemia
(HoFH).


Inclusion Criteria:

1. Men and women ≥18 years of age at the time of the screening visit

2. Diagnosis of homozygous familial hypercholesterolemia (HoFH)

3. Willing to consistently maintain usual diet for the duration of the study

Exclusion Criteria:

1. Background medical lipid modifying therapy that has not been stable for at least 4
weeks (6 weeks for fibrates) prior to the screening visit

2. Having undergone lipid apheresis within 4 weeks prior to the screening visit

3. Use of another investigational drug or therapy within 30 days or at least 5 half-lives
(whichever is longer) prior to the screening visit

4. Previous participation in any clinical trial of REGN1500

Note: The information listed above is not intended to contain all considerations relevant
to a patient's potential participation in this clinical trial therefore not all inclusion/
exclusion criteria are listed.
We found this trial at
5
sites
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Chicoutimi,
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials